← All trials
NCT05560399
Early Phase 1Interventional
Exploratory trials, involving very limited human exposure, with no therapeutic or diagnostic intent (e.g., screening studies, microdose studies).
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 15, 2022
- Primary completion
- Dec 15, 2023
- Completion date
- Aug 31, 2025
- First posted
- Sep 29, 2022
- Last posted
- Sep 29, 2022
- Enrollment
- 31
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Icahn School of Medicine at Mount SinaiLead sponsor
- Icahn School of Medicine at Mount SinaiOverall official - principal investigator
- Icahn School of Medicine at Mount SinaiStudy chair
- Icahn School of Medicine at Mount SinaiReponsible party - principal investigator
- Multiple Myeloma Research ConsortiumCollaborator
- Icahn School of Medicine at Mount SinaiSponsor investigator
- Bristol-Myers SquibbCollaborator
- Icahn School of Medicine at Mount SinaiOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.